STING Agonist Cuts TNBC Tumor Recurrence and Extends Survival in Mice
Pharmaceutical STING activation reduced primary tumor recurrence and extended survival in a mouse model of metastatic triple negative breast cancer.
Pharmaceutical STING activation reduced primary tumor recurrence and extended survival in a mouse model of metastatic triple negative breast cancer.
A four-patient PET study found that the activated T cell tracer F-AraG is best quantified with a two-tissue irreversible model ...
A novel intravenous STING agonist, BI 1703880, synergises with radiotherapy and checkpoint inhibitors to generate durable anti-tumour immunity in preclinical ...
A new mouse study shows that activating the cGAS-STING immune pathway early after spinal cord injury and inhibiting it later ...
A metal–organic framework nanovaccine co-delivering tumour antigens and STING agonists induced systemic tumour regression, immune memory and synergy with radiotherapy ...
Researchers have engineered a 3D-printed hydrogel scaffold that kills residual bone tumor cells through pH-responsive nanozyme catalysis, activates antitumor immunity ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.